SCHEMBL31651998

SCHEMBL31651998

COc1ccc(C)nc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 2/20 0.53
TLR9 Q9NR96 4/20 0.52
TLR7 Q9NYK1 2/20 0.48
GPR119 Q8TDV5 3/20 0.47
CKS1B P61024 1/20 0.46
SKP1 P63208 1/20 0.46
SKP2 Q13309 1/20 0.46
SUV39H2 Q9H5I1 2/20 0.46
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
GBA1 P04062 2/20 0.45
MEN1 O00255 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAP4K4 O95819 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
OGFRL1 Q5TC84 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31652004 0.86 TLR9 (0.51) SMPD3TLR9TLR7GPR119CKS1B
SCHEMBL17310150 0.86 TLR9 (0.51) SMPD3TLR9TLR7GPR119CKS1B
SCHEMBL31651790 0.86 TLR9 (0.51) SMPD3TLR9TLR7GPR119CKS1B
SCHEMBL31651709 0.84 TLR9 (0.49) SMPD3TLR9TLR7GPR119CKS1B
SCHEMBL31652099 0.82 TLR9 (0.54) SMPD3TLR9TLR7GPR119CKS1B
SCHEMBL31651803 0.82 TLR9 (0.47) SMPD3TLR9TLR7GPR119CKS1B
SCHEMBL31651781 0.80 TLR9 (0.49) SMPD3TLR9TLR7GPR119CKS1B
SCHEMBL11359476 0.80 POLB (0.55) TLR9TLR7GPR119CKS1BSKP1
SCHEMBL31651630 0.80 TLR9 (0.52) SMPD3TLR9TLR7GPR119SUV39H2
SCHEMBL31651640 0.80 TLR9 (0.52) SMPD3TLR9TLR7GPR119SUV39H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A SMPD3 2793/4885TLR9 301/4885TLR7 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.